621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides crucial evidence supporting the safety and continued efficacy of Semaglutide in a highly vulnerable patient population. For patients with type 2 diabetes and end-stage renal disease (ESRD) on dialy…
This case report is crucial for increasing clinical awareness regarding the potential for severe altered mental status as a manifestation of amantadine withdrawal. It underscores the importance of a thorough medicatio…
This comprehensive benchmarking study provides invaluable guidance for pharmaceutical scientists and quality control laboratories in selecting the most efficient and effective SEC columns. By optimizing SEC methods, r…
This study provides compelling evidence that semaglutide 1.7 mg is a highly effective and generally well-tolerated treatment option for adolescent obesity, a condition with limited pharmacological interventions. Given…
This study highlights a critical emerging trend in plastic surgery, demonstrating how advancements in pharmacotherapy for weight loss directly influence the demand for body contouring procedures. Understanding this sh…
This comprehensive meta-analysis provides robust evidence supporting the cardioprotective effects and favorable safety profile of GLP-1 Receptor Agonists in elderly patients with Type 2 Diabetes. Given the high burden…
This study provides crucial real-world evidence supporting the efficacy and safety of GLP-1 Receptor Agonists for managing Type 2 Diabetes in older adults, a population often underrepresented in initial clinical trial…
This comprehensive review underscores the critical role GLP-1 Receptor Agonists can play in managing Chronic Kidney Disease, moving beyond their traditional use in diabetes and obesity. The consistent evidence of sign…
This comprehensive review underscores that Semaglutide represents a significant therapeutic advancement, extending its benefits far beyond glucose control. Its dual cardioprotective and nephroprotective actions positi…
This research provides compelling evidence that GLP-1RAs possess direct antiarrhythmic properties, significantly extending their known cardiovascular benefits beyond glycemic control and weight loss. The observed subs…
This research underscores the chronic nature of obesity and highlights that GLP-1 receptor agonists function as effective long-term management tools rather than curative treatments. The rapid weight regain and metabol…
The patient presented with classic symptoms indicative of small bowel obstruction (SBO), including severe, colicky abdominal pain, persistent nausea, and intractable vomiting, leading to significant dehydration. Initi…
This research highlights the significant potential of GLP-1 receptor agonists as a novel pharmacological approach for treating Alcohol Use Disorder. The substantial reduction in alcohol intake and relapse-like behavio…
The findings from such a study are profoundly significant, as they suggest semaglutide could be more than just a weight-loss drug, offering a direct therapeutic benefit for obstructive sleep apnea. This represents a n…
This research provides novel insights into the neuroprotective mechanisms of Semaglutide, demonstrating its ability to combat obesity-linked neurodegeneration by modulating microglia activation and AD-like pathology t…
These findings provide crucial insights into the complex regulatory network within pancreatic islets, highlighting the dynamic and glucose-dependent role of δ cells in modulating α cell function. Understanding how gly…
This research provides crucial insights into the structural stability and aggregation mechanisms of semaglutide, which is vital for optimizing its formulation and storage. Understanding the pH-dependent formation of β…
These findings highlight FGF15 as a crucial endocrine factor that orchestrates beneficial adaptations in lean mass, bone, and bile acid metabolism during weight loss. The ability of exogenous FGF15 to mitigate the det…
This study provides crucial real-world data on the prevalence of hair shedding among GLP-1 RA users, definitively identifying rapid weight loss as a key contributing factor. Understanding this common side effect can h…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage ex…
This study provides crucial evidence for the comparative effectiveness of next-generation incretin therapies, offering valuable insights for clinicians. The findings suggest that Tirzepatide may be the preferred choic…
This study provides crucial real-world evidence supporting the use of GLP-1 RAs in solid-organ transplant recipients, a population often excluded from pivotal trials due to complex medical profiles. The superior effic…
This study highlights a significant and rapid shift in GLP-1 agonist utilization patterns, extending well beyond their primary indication for type 2 diabetes into the non-diabetic population. The substantial increase …
This study highlights the critical challenge of maintaining weight loss after discontinuing potent anti-obesity medications like Semaglutide and Tirzepatide in a real-world clinical setting. It underscores the need fo…
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This comprehensive meta-analysis solidifies the role of GLP-1 receptor agonists as highly effective pharmacological interventions for obesity management, providing strong evidence for their widespread clinical adoptio…
This study provides compelling real-world evidence that Tirzepatide, a dual GLP-1 and GIP receptor agonist, may offer superior neuroprotection compared to semaglutide (a GLP-1 receptor agonist) in patients with type 2…
This joint guidance statement represents a significant step forward in standardizing and optimizing the pharmacological management of overweight and obesity in the United States. By providing clear, evidence-based rec…
This study highlights a critical concern: while GLP-1 receptor agonists are highly effective for weight loss, the potential for significant lean muscle mass loss needs careful consideration. Preserving muscle is vital…
This 2026 Update provides crucial, up-to-date, and evidence-based recommendations that will significantly impact the clinical management of MASLD and MASH globally. By clearly outlining the efficacy of various pharmac…
This post-hoc analysis highlights the critical importance of early treatment response as a predictor of overall success with tirzepatide and semaglutide for obesity. The findings suggest that monitoring early weight l…
The profound influence of social media on public health discourse and patient behavior is a critical concern, particularly for highly sought-after medications like GLP-1 RAs. This research underscores an urgent need f…
This systematic review highlights a novel and potentially impactful therapeutic avenue for patients suffering from Hidradenitis Suppurativa, particularly those with underlying metabolic comorbidities. Repurposing exis…
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
This study highlights that not all GLP-1 RAs are interchangeable regarding their safety profiles, providing crucial insights for personalized medicine. Clinicians can use this real-world evidence to make more informed…
This review highlights the significant challenge of maintaining weight loss and cardiometabolic improvements after discontinuing GLP-1 RA therapy, emphasizing that obesity is a chronic disease requiring long-term mana…
This study provides compelling real-world evidence suggesting tirzepatide offers superior cardiovascular protection compared to semaglutide in non-diabetic individuals with obesity. These findings are crucial for guid…
These findings are crucial for informing prescribing practices and patient monitoring for individuals on GLP-1 RAs, especially those with pre-existing diabetic eye disease. Given the widespread and increasing use of t…
This study provides crucial real-world insights into the safety profile of GLP-1 RAs, emphasizing the importance of monitoring for psychiatric adverse events beyond controlled clinical trial settings. The identificati…
This comprehensive review is critical for guiding clinicians and policymakers in India to implement evidence-based and effective obesity management strategies. By synthesizing the latest data and expert consensus from…
This review underscores the rapid and profound evolution of obesity pharmacotherapy, offering unprecedented hope for patients struggling with chronic weight management. The development of highly effective drugs like G…
This hypothetical study strongly suggests that integrating resistance exercise with incretin-based weight loss pharmacotherapy is critical for optimizing body composition, mitigating sarcopenia (age-related muscle los…
The development of oral GLP-1 RAs represents a significant leap forward, offering a more convenient and patient-friendly option that can greatly improve adherence to treatment for Type 2 Diabetes. Furthermore, the adv…
This comprehensive comparison provides crucial evidence for clinicians and patients, guiding treatment decisions for obesity and overweight. The identification of most effective agents can lead to more personalized an…